Da An Gene Co Ltd of Sun Yat-Sen University (002030) - Net Assets

Latest as of March 2026: CN¥7.27 Billion CNY ≈ $1.06 Billion USD

Based on the latest financial reports, Da An Gene Co Ltd of Sun Yat-Sen University (002030) has net assets worth CN¥7.27 Billion CNY (≈ $1.06 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.33 Billion ≈ $1.22 Billion USD) and total liabilities (CN¥1.07 Billion ≈ $156.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Da An Gene Co Ltd of Sun Yat-Sen Univers tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥7.27 Billion
% of Total Assets 87.19%
Annual Growth Rate 23.07%
5-Year Change -3.85%
10-Year Change 188.46%
Growth Volatility 46.31

Da An Gene Co Ltd of Sun Yat-Sen University - Net Assets Trend (2001–2025)

This chart illustrates how Da An Gene Co Ltd of Sun Yat-Sen University's net assets have evolved over time, based on quarterly financial data. See 002030 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Da An Gene Co Ltd of Sun Yat-Sen University (2001–2025)

The table below shows the annual net assets of Da An Gene Co Ltd of Sun Yat-Sen University from 2001 to 2025. For live valuation and market cap data, see market cap of Da An Gene Co Ltd of Sun Yat-Sen Univers.

Year Net Assets Change
2025-12-31 CN¥7.36 Billion
≈ $1.08 Billion
-9.56%
2024-12-31 CN¥8.14 Billion
≈ $1.19 Billion
-11.07%
2023-12-31 CN¥9.16 Billion
≈ $1.34 Billion
-21.17%
2022-12-31 CN¥11.62 Billion
≈ $1.70 Billion
+51.64%
2021-12-31 CN¥7.66 Billion
≈ $1.12 Billion
+69.67%
2020-12-31 CN¥4.51 Billion
≈ $660.64 Million
+116.27%
2019-12-31 CN¥2.09 Billion
≈ $305.47 Million
-5.14%
2018-12-31 CN¥2.20 Billion
≈ $322.01 Million
-16.70%
2017-12-31 CN¥2.64 Billion
≈ $386.56 Million
+3.47%
2016-12-31 CN¥2.55 Billion
≈ $373.61 Million
+31.63%
2015-12-31 CN¥1.94 Billion
≈ $283.84 Million
+112.07%
2014-12-31 CN¥914.64 Million
≈ $133.84 Million
+20.65%
2013-12-31 CN¥758.10 Million
≈ $110.93 Million
+21.06%
2012-12-31 CN¥626.21 Million
≈ $91.63 Million
+13.01%
2011-12-31 CN¥554.12 Million
≈ $81.09 Million
+14.88%
2010-12-31 CN¥482.34 Million
≈ $70.58 Million
+12.54%
2009-12-31 CN¥428.60 Million
≈ $62.72 Million
+11.24%
2008-12-31 CN¥385.31 Million
≈ $56.38 Million
+24.63%
2007-12-31 CN¥309.15 Million
≈ $45.24 Million
+10.14%
2006-12-31 CN¥280.69 Million
≈ $41.07 Million
+4.08%
2005-12-31 CN¥269.70 Million
≈ $39.47 Million
+5.06%
2004-12-31 CN¥256.72 Million
≈ $37.57 Million
+178.80%
2003-12-31 CN¥92.08 Million
≈ $13.47 Million
+33.40%
2002-12-31 CN¥69.03 Million
≈ $10.10 Million
+36.68%
2001-12-31 CN¥50.50 Million
≈ $7.39 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Da An Gene Co Ltd of Sun Yat-Sen University's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 34342.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥3.87 Billion 54.18%
Other Components CN¥3.27 Billion 45.82%
Total Equity CN¥7.14 Billion 100.00%

Da An Gene Co Ltd of Sun Yat-Sen University Competitors by Market Cap

The table below lists competitors of Da An Gene Co Ltd of Sun Yat-Sen University ranked by their market capitalization.

Company Market Cap
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
$1.14 Billion
Radware Ltd
NASDAQ:RDWR
$1.14 Billion
ZYNP Corp
SHE:002448
$1.14 Billion
Zhejiang Chenfeng Science and Technology Co Ltd Class A
SHG:603685
$1.14 Billion
COMPUGROUP MED.SP.ADR 1
F:COPA
$1.14 Billion
AirAsia X Bhd
KLSE:5238
$1.14 Billion
Fiyta Holdings Ltd
SHE:000026
$1.14 Billion
M. Dias Branco S.A. Indústria e Comércio de Alimentos
SA:MDIA3
$1.14 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Da An Gene Co Ltd of Sun Yat-Sen University's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 7,879,949,193 to 7,137,861,023, a change of -742,088,170 (-9.4%).
  • Net loss of 744,378,902 reduced equity.
  • Dividend payments of 8,457,273 reduced retained earnings.
  • Other comprehensive income decreased equity by 1,763,163,151.
  • Other factors increased equity by 1,773,911,155.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥-744.38 Million -10.43%
Dividends Paid CN¥8.46 Million -0.12%
Other Comprehensive Income CN¥-1.76 Billion -24.7%
Other Changes CN¥1.77 Billion +24.85%
Total Change CN¥- -9.42%

Book Value vs Market Value Analysis

This analysis compares Da An Gene Co Ltd of Sun Yat-Sen University's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.09x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 157.17x to 1.09x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.04 CN¥5.55 x
2002-12-31 CN¥0.05 CN¥5.55 x
2003-12-31 CN¥0.07 CN¥5.55 x
2004-12-31 CN¥0.22 CN¥5.55 x
2005-12-31 CN¥0.23 CN¥5.55 x
2006-12-31 CN¥0.24 CN¥5.55 x
2007-12-31 CN¥0.25 CN¥5.55 x
2008-12-31 CN¥0.29 CN¥5.55 x
2009-12-31 CN¥0.26 CN¥5.55 x
2010-12-31 CN¥0.29 CN¥5.55 x
2011-12-31 CN¥0.34 CN¥5.55 x
2012-12-31 CN¥0.41 CN¥5.55 x
2013-12-31 CN¥0.50 CN¥5.55 x
2014-12-31 CN¥0.60 CN¥5.55 x
2015-12-31 CN¥0.95 CN¥5.55 x
2016-12-31 CN¥1.17 CN¥5.55 x
2017-12-31 CN¥1.21 CN¥5.55 x
2018-12-31 CN¥1.29 CN¥5.55 x
2019-12-31 CN¥1.31 CN¥5.55 x
2020-12-31 CN¥3.04 CN¥5.55 x
2021-12-31 CN¥5.24 CN¥5.55 x
2022-12-31 CN¥8.05 CN¥5.55 x
2023-12-31 CN¥6.33 CN¥5.55 x
2024-12-31 CN¥5.62 CN¥5.55 x
2025-12-31 CN¥5.09 CN¥5.55 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Da An Gene Co Ltd of Sun Yat-Sen University utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -10.43%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -98.25%
  • • Asset Turnover: 0.09x
  • • Equity Multiplier: 1.19x
  • Recent ROE (-10.43%) is below the historical average (15.63%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 28.43% 19.54% 0.72x 2.01x CN¥9.13 Million
2002 27.25% 18.17% 0.78x 1.92x CN¥11.75 Million
2003 25.23% 17.43% 0.75x 1.93x CN¥13.94 Million
2004 9.84% 16.17% 0.50x 1.22x CN¥-416.85K
2005 9.81% 16.19% 0.55x 1.11x CN¥-514.16K
2006 10.41% 16.66% 0.53x 1.18x CN¥1.13 Million
2007 11.49% 16.90% 0.49x 1.40x CN¥4.53 Million
2008 10.66% 14.61% 0.45x 1.62x CN¥2.15 Million
2009 12.80% 14.82% 0.55x 1.58x CN¥10.36 Million
2010 13.41% 15.26% 0.55x 1.60x CN¥14.35 Million
2011 13.85% 14.86% 0.58x 1.60x CN¥18.92 Million
2012 15.73% 15.47% 0.64x 1.59x CN¥32.84 Million
2013 20.50% 16.83% 0.74x 1.65x CN¥73.62 Million
2014 17.97% 14.09% 0.68x 1.87x CN¥67.90 Million
2015 7.63% 6.87% 0.48x 2.29x CN¥-31.47 Million
2016 6.63% 6.62% 0.39x 2.57x CN¥-54.26 Million
2017 5.15% 5.60% 0.33x 2.76x CN¥-81.56 Million
2018 5.59% 6.87% 0.40x 2.02x CN¥-80.00 Million
2019 5.01% 8.39% 0.31x 1.93x CN¥-91.97 Million
2020 57.37% 45.85% 0.80x 1.57x CN¥2.02 Billion
2021 49.22% 47.21% 0.74x 1.41x CN¥2.88 Billion
2022 47.89% 44.93% 0.82x 1.31x CN¥4.28 Billion
2023 1.18% 8.86% 0.11x 1.24x CN¥-783.36 Million
2024 -11.74% -108.46% 0.09x 1.22x CN¥-1.71 Billion
2025 -10.43% -98.25% 0.09x 1.19x CN¥-1.46 Billion

Industry Comparison

This section compares Da An Gene Co Ltd of Sun Yat-Sen University's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $5,744,144,451
  • Average return on equity (ROE) among peers: 1.06%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Da An Gene Co Ltd of Sun Yat-Sen University (002030) CN¥7.27 Billion 28.43% 0.15x $1.14 Billion
Shenzhen CAU Technology Co Ltd (000004) $1.40 Billion -0.26% 0.06x $53.47 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $966.91 Million 19.23% 0.71x $1.50 Billion
Nanhua Bio Medicine Co Ltd (000504) $128.43 Million -28.90% 2.15x $378.62 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $512.78 Million -14.68% 0.29x $470.05 Million
Chengzhi Shareholding Co Ltd (000990) $1.69 Billion 3.06% 0.97x $1.54 Billion
Hualan Biological EngineeringInc (002007) $13.85 Billion 7.86% 0.18x $3.43 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252) $29.65 Billion 6.00% 0.08x $4.52 Billion
Baolingbao Biology Co Ltd (002286) $1.45 Billion 1.65% 0.22x $496.75 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $2.05 Billion 15.59% 0.13x $1.64 Billion

About Da An Gene Co Ltd of Sun Yat-Sen University

SHE:002030 China Biotechnology
Market Cap
$1.14 Billion
CN¥7.79 Billion CNY
Market Cap Rank
#8495 Global
#2093 in China
Share Price
CN¥5.55
Change (1 day)
+2.02%
52-Week Range
CN¥5.29 - CN¥7.71
All Time High
CN¥25338.45
About

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coro… Read more